FIELD: medicine.
SUBSTANCE: invention relates to a method of treating glioblastoma in a subject by administering a therapeutically effective amount of an antibody or antigen-binding portion thereof, which specifically binds to the programmed death-1 receptor (PD-1) and inhibits PD-1 ("anti-PD-1"), and temozolomide activity.
EFFECT: method enables higher clinical effectiveness in glioblastoma ensured by a synergistic effect of the combination.
53 cl, 17 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| ANTIBODIES TO B7-H1 AND TO CTLA-4 FOR TREATING NON-SMALL-CELL LUNG CANCER | 2015 |
|
RU2702332C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| COMBINATION | 2015 |
|
RU2744841C2 |
